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No established treatment exists for urachal carcinoma, except curative resection, and its prognosis is
poor. More than 80% of urachal carcinomas are adenocarcinomas. We report a case of advanced urachal
carcinoma treated with S-1 and cisplatin combination (S-1/CDDP) chemotherapy. The patient, a 61-year-
old woman, presented with macroscopic hematuria. A tumor was detected on the bladder dome and
transurethral resection was performed. Histopathological findings indicated poorly differentiated
adenocarcinoma. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels were 3.5 ng/ml
and 140 U/ml respectively. Magnetic resonance images indicated an extension of this tumor to the
retroperioneal space. Metastasis to her right ischium was suspected from bone scintigraphy results. The
tumor was diagnosed as stage IVB (Sheldon’s category) urachal carcinoma. After one cycle of S-1/CDDP
chemotherapy, the size of the tumor on the bladder dome decreased, after which total cystectomy was
performed. The surgical margin of the cystectomy specimen was negative for malignant cells, although
poorly differentiated adenocarcinoma was still observed in this specimen. The findings of this study indicate
that this therapy might be beneficial for treating advanced urachal carcinomas. This is the second report of
successful treatment of advanced urachal carcinoma with S-1/CDDP chemotherapy.
(Hinyokika Kiyo 56 : 447-451, 2010)

























入院時現症 : 身長 154 cm，体重 35 kg，腹部平坦，
血圧 160/82 mmHg，脈拍110回/分．
血液生化学検査 : WBC 10,400/ml，Hb 13.9 g/dl，
LDH 204 IU/l，ALP 385 IU/l，Cre 0.8 mg/dl，空腹時
血糖 169 mg/dl，HbA1c 8.0％
血清免疫学的検査 : CRP 0.5 mg/dl，CEA 3.5（正
常値 : 0∼5) ng/ml，CA19-9 140（正常値 : 0∼37)
U/ml
泌尿紀要 56 : 447-451，2010年 447
尿沈渣 : RBC 10∼19/HPF，WBC 5∼9/HPF
尿細胞診 : class V
画像検査所見 : 骨盤部 MRI において膀胱前壁から
頂部の著明な肥厚と膀胱外への腫瘍の進展が認められ
た (Fig. 1）．骨シンチグラフィーでは右坐骨部への集











法に準じ S-1（ティーエスワン○R）(80 mg/m2) を day
1∼21 内服し 2週間休薬，シスプラチン (60 mg/m2)

















られておらず，CA19-9 は 11 U/ml と低値を維持して
いる．














Fig. 1. Pre-chemotheraputic image : Sagittal MRI
film shows the tumor on the bladder dome
(white arrow head).
泌56,08,05-2
Fig. 2. Bone scintigraphy shows increased uptake to
her right ischium.
泌56,08,05-3
Fig. 3. After one course of chemotherapy, the size
of this tumor decreased (white arrow head).
泌尿紀要 56巻 8号 2010年448
であり，組織学的には80％以上が腺癌である．そのた
































ある S-1 はテガフールに 2つのモジュレーター，ギメ
ラシルとオテラシルカリウムを配合することにより
泌56,08,05-4A
Fig. 4A. Histopathological finding shows invasive
proliferation of malignant cells and infil-
tration of lymphocytes (HE stain ×40).
泌56,08,05-4B
Fig. 4B. Microscopic appearance of poorly differ-
entiated adenocarcinoma (HE stain ×
400).
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Fig. 4C. Multinucleated cell and pycnotic cells are
shown arround the tumor cells (HE stain
×400).
泌56,08,05-5
Fig. 5. Pre-chemotheraputic appearance of tumor
cells (HE stain ×400).






の標準的治療の 1つとなった．また，S-1 の 5-FU に
対する非劣性が証明されたこともあり13)，われわれ
はピリミジン拮抗薬として S-1 を選択した．S-1 は単
独投与でも高い奏効率が示されているが，胃癌に対す
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